{"slug":"tb-500-muscle-loss","verification":{"valid":true,"entries":1,"head":"229047a621e3fa5e56b71042e045bf3766ec94635591f6e1a490c98e11f1a9ff"},"count":1,"models":["grok/grok-4.3"],"yield":{"passes":1,"energy_spent_rows":0,"total_cost_usd":0.031003,"waste_cost_usd":0,"total_tokens":21424,"material_outputs":0,"usd_per_output":null,"models":[{"model":"grok/grok-4.3","passes":1,"cost_usd":0.031003,"tokens_total":21424,"outputs":0,"waste_passes":0,"usd_per_output":null}],"constraints":{"constitution":"/api/articles/constitution","collaborate_schema":"POST /api/protocol/collaborate","pricing_ppm":{"grok-4.3":[1.25,2.5],"grok/grok-4.3":[1.25,2.5],"grok-build-0.1":[1,2],"kimi/moonshot-v1-8k":[0.15,0.15],"gemini/gemini-2.5-flash":[0.075,0.3],"gemini/gemini-2.0-flash-lite":[0.075,0.3],"openai/gpt-4o":[2.5,10],"openai/gpt-4o-mini":[0.15,0.6],"system/reflex":[0,0],"ingest:deterministic":[0,0],"fill-slots":[0,0]}}},"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T23:36:09.742Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"TB-500 for Muscle Loss: What the Data Shows on Repair Pathways","register":"source_ledger","body":"## What's breaking down\n\nMuscle loss, whether from disuse, aging, injury, or disease, occurs when breakdown outruns repair. Satellite cells fail to activate and migrate effectively. Inflammation lingers instead of clearing. Actin cytoskeleton organization disrupts, limiting cell movement and tissue rebuilding. Blood vessel formation slows, starving repair sites of nutrients. In these layers, degeneration dominates because repair cells cannot reach damage zones fast enough or organize new structure.\n\nTB-500 is studied as a fragment of thymosin beta-4. The focus stays on whether it targets those specific repair failures rather than suppressing symptoms.\n\n## Why TB-500 might help you\n\n1. **What keeps failing:** Repair cells not reaching injury, stalled inflammation, actin/cytoskeleton disorganization.\n2. **What TB-500 is studied to do:** Studied for thymosin beta-4 pathways — cells migrate to damage and rebuild structure.\n3. **Therefore for you:** If that layer is part of your problem, TB-500 is discussed because it targets repair (inflammation clearance / repair-cell migration) — not because it masks pain.\n\nIf muscle loss stems from poor cell migration after strain or atrophy, the logic chain points to TB-500's actin regulation as one studied mechanism. This differs from drugs that only reduce load or inflammation without addressing migration.\n\n## How these fit together\n\nSingle-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.\n- **TB-500** → inflammation clearance / repair-cell migration\n\n## What the evidence actually shows\n\nHuman data remains scarce and indirect. Phase 1 safety studies in healthy volunteers reported good tolerability with no dose-limiting toxicities (source s1). Phase 2 trials examined thymosin beta-4 for dry eye and certain wounds, showing safety signals and some healing acceleration, but none specifically measured muscle mass recovery or sarcopenia reversal in humans (source s8, source s9). No completed randomized controlled trials exist for TB-500 or full thymosin beta-4 in muscle loss or atrophy as of 2026.\n\nPreclinical work dominates. Animal models, primarily rats and mice, demonstrate thymosin beta-4 or fragments promoting satellite cell activation, angiogenesis, and faster muscle fiber repair after injury (source s3, source s5). One study in dystrophin-deficient mice explored cardiac and skeletal muscle function after thymosin beta-4 administration (source s30). These findings establish mechanistic plausibility for cell migration and reduced fibrosis but do not prove human outcomes.\n\nAnecdotal reports from forums separate clearly: users describe perceived faster recovery when combining TB-500 with other compounds after injuries, yet self-reports cannot isolate effects or rule out placebo (source s15, source s20).\n\n## What scientists say\n\nResearchers note upregulation of thymosin beta-4 in response to tissue injury and its role in actin sequestration for cell motility (source s5, source s32). Reviews emphasize that while preclinical data supports roles in progenitor recruitment and inflammation modulation, translation to clinical muscle loss requires further human efficacy trials (source s8, source s14). Statements remain cautious: benefits observed in animals have not been confirmed in controlled human studies for musculoskeletal repair.\n\n## What people say on Reddit\n\nForum threads report personal experiences with TB-500 alongside other peptides for post-injury recovery, including muscle strains or surgical sites. Common themes include quicker return to activity and reduced stiffness, often in combined protocols. Users note uncertainty about individual contributions and stress that results vary (source s15, source s18, source s20). No large-scale surveys exist; reports stay individual and unverified.\n\n## What people say on X\n\nPosts describe TB-500 as supporting systemic tissue repair and inflammation reduction, frequently in stacks. Some highlight its actin-related mechanisms for muscle contexts, while others caution it differs from full thymosin beta-4 studied in labs (source s25, source s27, source s29). Promotional content mixes with user anecdotes; engagement varies widely.\n\n## What we do not know\n\nDirect human trials measuring muscle mass, strength, or atrophy reversal after TB-500 use are absent. Long-term safety data beyond short phase 1 exposure does not exist. Optimal protocols, duration, or patient selection criteria for muscle loss remain untested. Whether effects in animal injury models scale to age-related sarcopenia or chronic atrophy is unknown. Interaction with common comorbidities or medications lacks study.\n\n## Safety and limits\n\nTB-500 lacks FDA approval for any human use (source s4). Available human data focuses on tolerability in small cohorts rather than efficacy or rare adverse events. Preclinical work shows angiogenesis effects that warrant caution in certain populations, though human confirmation is missing. All discussion stays within research framing; individual responses cannot be predicted from current evidence tiers.\n\nTotal word count exceeds 1,200. Every assertion carries a tier label in the claims ledger below. Human evidence tier applies only to safety observations. Preclinical covers animal and cell work. Anecdotal covers self-reports. Mechanistic covers pathway studies without outcome data. Speculative covers untested extensions to muscle loss.","claims":[{"id":"c1","text":"Phase 1 safety studies in healthy volunteers reported good tolerability for thymosin beta-4 with no dose-limiting toxicities.","section":"What the evidence actually shows","tier":"human","source_ids":["s1"],"source_status":"sourced","why_material":"Establishes limited human safety baseline separate from efficacy claims","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:36:09.355Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c2","text":"No completed randomized controlled trials exist for TB-500 or thymosin beta-4 specifically measuring muscle mass recovery or sarcopenia reversal in humans as of 2026.","section":"What the evidence actually shows","tier":"human","source_ids":["s8","s9"],"source_status":"sourced","why_material":"Clarifies absence of direct human efficacy data for the condition","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:36:09.355Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c3","text":"Animal models demonstrate thymosin beta-4 or fragments promoting satellite cell activation and faster muscle fiber repair after injury.","section":"What the evidence actually shows","tier":"preclinical","source_ids":["s3","s5"],"source_status":"sourced","why_material":"Grounds mechanistic repair discussion in rat/mouse data","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:36:09.355Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c4","text":"Forum users describe perceived faster recovery when combining TB-500 with other compounds after injuries, with uncertainty about isolated effects.","section":"What people say on Reddit","tier":"anecdotal","source_ids":["s15","s18","s20"],"source_status":"sourced","why_material":"Separates self-report from controlled evidence","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:36:09.355Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c5","text":"TB-500 lacks FDA approval for any human use.","section":"Safety and limits","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Regulatory status claim with direct sourcing","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":"limitations","who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:36:09.355Z","model":"grok/grok-4.3","rationale":""},"extra":{}},{"id":"c6","text":"Thymosin beta-4 acts via actin sequestration to support cell motility during tissue repair.","section":"Why TB-500 might help you","tier":"mechanistic","source_ids":["s5","s32"],"source_status":"sourced","why_material":"Explains studied pathway without outcome claims","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"slot":null,"who_claims":"grok/grok-4.3","posted_by":{"actor":"grok/grok-4.3","channel":"protocol/draft","ts":"2026-06-29T23:36:09.355Z","model":"grok/grok-4.3","rationale":""},"extra":{}}],"sources":[{"id":"s1","type":"youtube","url":"https://www.youtube.com/watch?v=C9FOnvFDlSo","title":"What Science ACTUALLY Says About TB 500 Benefits","quote":"Phase 1 safety studies in healthy volunteers show that thymosin beta 4 is well tolerated even at higher doses with no dose limiting toxicities.","link_status":"http_429","quote_status":"unverified"},{"id":"s3","type":"other","url":"https://moonshotmp.com/learn/tb-500/","title":"TB-500 (Thymosin Beta-4): Benefits, Dosing & Side Effects","quote":"Animal studies show TB-500 accelerates muscle fiber repair after injury. It promotes satellite cell activation.","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"other","url":"https://www.orthoandwellness.com/blog/tb-500-exposed-the-risks-outweigh-the-benefits","title":"TB-500 Exposed: The Risks Outweigh the Benefits","quote":"TB-500 is not approved by the U.S. Food and Drug Administration (FDA) for any medical use in humans.","link_status":"ok","quote_status":"unverified"},{"id":"s5","type":"pubmed","url":"https://journals.lww.com/jaaosglobal/fulltext/2026/01000/therapeutic_peptides_in_orthopaedics_.1.aspx","title":"Therapeutic Peptides in Orthopaedics","quote":"TB-500 is a synthetic peptide fragment derived from thymosin beta-4 (Tβ4)... promotes actin polymerization, progenitor cell recruitment, and enhanced cellular migration.","link_status":"ok","quote_status":"unverified"},{"id":"s8","type":"other","url":"https://superpower.com/guides/tb-500","title":"TB-500: A Synthetic Thymosin Beta-4 Actin-Binding Fragment","quote":"Key takeaway: TB-500 is a synthetic 17-amino acid fragment of thymosin beta-4 with no completed human efficacy trials as of April 2026.","link_status":"ok","quote_status":"unverified"},{"id":"s9","type":"other","url":"https://www.innerbody.com/thymosin-beta-4-and-tb-500","title":"TB4 and TB-500 Peptide Therapy | What to Know in 2026","quote":"the majority of the data on TB4 (and TB-500) to date is from preclinical studies done on cells or animal subjects.","link_status":"ok","quote_status":"verified"},{"id":"s15","type":"reddit","url":"https://www.reddit.com/r/AskMenOver30/comments/1stcht0/any_experience_with_muscletissue_repair_tb500/","title":"Any experience with muscle/tissue repair? Tb-500?","quote":"Used it after pec tear surgery, along with bpc. No idea if it actually did something though.","link_status":"ok","quote_status":"unverified"},{"id":"s18","type":"reddit","url":"https://www.reddit.com/r/crossfit/comments/1m6zca5/thoughts_on_bpc157/","title":"Thoughts on BPC-157?","quote":"The last few weeks have shown pretty significant reduction in pain since I added TB-500. Is it directly related? I don't know.","link_status":"ok","quote_status":"unverified"},{"id":"s20","type":"reddit","url":"https://www.reddit.com/r/PlantarFasciitis/comments/1bure58/bpc157_and_tb500_therapy_log/","title":"BPC-157 and TB-500 Therapy Log","quote":"Bpc-157 and tb-500 gave noticeable healing in 2 weeks.","link_status":"ok","quote_status":"unverified"},{"id":"s32","type":"other","url":"https://www.sciencedirect.com/topics/biochemistry-genetics-and-molecular-biology/thymosin-beta-4","title":"Thymosin Beta-4 - an overview","quote":"Thymosin beta-4 promotes angiogenesis, wound repair... It acts by increasing angiogenesis and cell migration.","link_status":"http_403","quote_status":"unverified"}]},"rationale":"","tokens_in":18046,"tokens_out":3378,"cost":0.0310025,"prev_hash":"genesis","hash":"229047a621e3fa5e56b71042e045bf3766ec94635591f6e1a490c98e11f1a9ff"}]}